VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Search Videos by Topic or Participant
Browse by Series:

Reining in the Cost of Cancer Care

Panelists: Andrew L. Pecora, MD, FACP, CPE, JTCC
Published: Wednesday, May 27, 2015
For High-Definition, Click
Rising healthcare costs represent a national challenge and a “call to action,” which requires collaboration across platforms to devise practical solutions while keeping patients’ best interests at heart, says Andrew L. Pecora, MD.
 
Oncology physicians share in this responsibility, says the doctor. He has been involved in the creation of the Cancer Outcomes Tracking Analysis (COTA), a health outcomes measurement and tracking tool that Pecora says enables physicians to achieve the “Goldilocks” target—neither too much care, nor too little. 
 
Pecora says his fellow physicians have contributed to the development of the Centers for Medicare & Medicaid Services’ Oncology Care Model of improving value and reducing expense, along with other types of reimbursement models. 
Slider Left
Slider Right
For High-Definition, Click
Rising healthcare costs represent a national challenge and a “call to action,” which requires collaboration across platforms to devise practical solutions while keeping patients’ best interests at heart, says Andrew L. Pecora, MD.
 
Oncology physicians share in this responsibility, says the doctor. He has been involved in the creation of the Cancer Outcomes Tracking Analysis (COTA), a health outcomes measurement and tracking tool that Pecora says enables physicians to achieve the “Goldilocks” target—neither too much care, nor too little. 
 
Pecora says his fellow physicians have contributed to the development of the Centers for Medicare & Medicaid Services’ Oncology Care Model of improving value and reducing expense, along with other types of reimbursement models. 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x